Dipeptidyl peptidase IV inhibition exerts renoprotective effects in rats with established heart failure

Frontiers in Physiology

Volumn 7, Issue JUL, 2016, Pages

  Arruda, Daniel F ^a   Martins, Flavia L ^a   Dariolli, Rafael ^a   Jensen, Leonardo ^a   Antonio, Ednei L ^b   dos Santos, Leonardo ^c   Tucci, Paulo J F ^b   Girardi, Adriana C C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

Cardiorenal dysfunction; Fluid retention; Glucagon like peptide 1; Megalin; Proteinuria; Vildagliptin

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; MEGALIN; NEPHRIN; PODOCIN; PROTEIN; SODIUM; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME INHIBITION; FLUID RETENTION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE; KIDNEY CORTEX; MALE; NONHUMAN; PODOCYTE; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RADIOFREQUENCY ABLATION; RAT; RELAXATION TIME; RENAL PROTECTION; SODIUM URINE LEVEL; UPREGULATION; URINARY EXCRETION; URINE FLOW RATE;

EID: 84981508385     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2016.00293     Document Type: Article

References (69)

1. Agrawal, V., Prasad, N., Jain, M., and Pandey, R. (2013). Reduced podocin expression in minimal change disease and focal segmental glomerulosclerosis is related to the level of proteinuria. Clin. Exp. Nephrol. 17, 811-818. doi: 10.1007/s10157-013-0775-y
2. Antonio, E. L., Dos Santos, A. A., Araujo, S. R., Bocalini, D. S., Dos Santos, L., Fenelon, G., et al. (2009). Left ventricle radio-frequency ablation in the rat: a new model of heart failure due to myocardial infarction homogeneous in size and low in mortality. J. Card. Fail. 15, 540-548. doi: 10.1016/j.cardfail.2009.01.007
3. Aoyama, M., Kawase, H., Bando, Y. K., Monji, A., and Murohara, T. (2016). Dipeptidyl peptidase 4 inhibition alleviates shortage of circulating glucagon-like peptide-1 in heart failure and mitigates myocardial remodeling and apoptosis via the exchange protein directly activated by cyclic AMP 1/ras-related protein 1 axis. Circ. Heart Fail. 9:e002081. doi: 10.1161/CIRCHEARTFAILURE.115.002081
4. Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S. S., Drucker, D. J., and Husain, M. (2008). Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117, 2340-2350. doi: 10.1161/CIRCULATIONAHA.107.739938
5. Bao, W., Aravindhan, K., Alsaid, H., Chendrimada, T., Szapacs, M., Citerone, D. R., et al. (2011). Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS ONE 6:e23570. doi: 10.1371/journal.pone.0023570
6. Birn, H., and Christensen, E. I. (2006). Renal albumin absorption in physiology and pathology. Kidney Int. 69, 440-449. doi: 10.1038/sj.ki.5000141
7. Boerrigter, G., Hocher, B., and Lapp, H. (2013). Changes in renal function in congestive heart failure. Curr. Heart Fail. Rep. 10, 285-295. doi: 10.1007/s11897-013-0170-8
8. Boute, N., Gribouval, O., Roselli, S., Benessy, F., Lee, H., Fuchshuber, A., et al. (2000). NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat. Genet. 24, 349-354. doi: 10.1038/74166
9. Brum, P. C., Rolim, N. P., Bacurau, A. V., and Medeiros, A. (2006). Neurohumoral activation in heart failure: the role of adrenergic receptors. An. Acad. Bras. Cienc. 78, 485-503. doi: 10.1590/S0001-37652006000300009
10. Cadnapaphornchai, M. A., Gurevich, A. K., Weinberger, H. D., and Schrier, R. W. (2001). Pathophysiology of sodium and water retention in heart failure. Cardiology 96, 122-131. doi: 10.1159/000047396
11. Carney, E. F. (2016). Podocyte biology: phosphorylation preserves podocytes. Nat. Rev. Nephrol. 12, 197. doi: 10.1038/nrneph.2016.17
12. Chatterjee, K. (2005). Neurohormonal activation in congestive heart failure and the role of vasopressin. Am. J. Cardiol. 95, 8b-13b. doi: 10.1016/j.amjcard.2005.03.003
13. Crajoinas, R. O., Lessa, L. M., Carraro-Lacroix, L. R., Davel, A. P., Pacheco, B. P., Rossoni, L. V., et al. (2010). Posttranslational mechanisms associated with reduced NHE3 activity in adult vs. young prehypertensive SHR. Am. J. Physiol. Renal Physiol. 299, F872-F881. doi: 10.1152/ajprenal.00654.2009
14. Crajoinas, R. O., Oricchio, F. T., Pessoa, T. D., Pacheco, B. P., Lessa, L. M., Malnic, G., et al. (2011). Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am. J. Physiol. Renal Physiol. 301, F355-F363. doi: 10.1152/ajprenal.00729.2010
15. Crajoinas, R. O., Pessoa, T. D., Rodrigues, M. V., Malnic, G., and Girardi, A. C. (2014). Changes in the activity and expression of protein phosphatase-1 accompany the differential regulation of NHE3 before and after the onset of hypertension in spontaneously hypertensive rats. Acta Physiol. (Oxf). 211, 395-408. doi: 10.1111/apha.12288
16. de Almeida Salles, T., Zogbi, C., de Lima, T. M., de Godoi Carneiro, C., Garcez, A. T., Barbeiro, H. V., et al. (2016). The contributions of dipeptidyl peptidase IV to inflammation in heart failure. Am. J. Physiol. Heart Circ. Physiol. 310, H1760-H1772. doi: 10.1152/ajpheart.00735.2015
17. dos Santos, L., Mello, A. F., Antonio, E. L., and Tucci, P. J. (2008). Determination of myocardial infarction size in rats by echocardiography and tetrazolium staining: correlation, agreements, and simplifications. Braz. J. Med. Biol. Res. 41, 199-201. doi: 10.1590/S0100-879X2008005000007
18. dos Santos, L., Salles, T. A., Arruda-Junior, D. F., Campos, L. C., Pereira, A. C., Barreto, A. L., et al. (2013). Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circ. Heart Fail. 6, 1029-1038. doi: 10.1161/CIRCHEARTFAILURE.112.000057
19. Eun Lee, J., Kim, J. E., Lee, M. H., Song, H. K., Ghee, J. Y., Kang, Y. S., et al. (2016). DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury. Lab. Invest. 96, 547-560. doi: 10.1038/labinvest.2016.34
20. Farah, L. X., Valentini, V., Pessoa, T. D., Malnic, G., McDonough, A. A., and Girardi, A. C. (2016). The physiological role of glucagon-like peptide-1 in the regulation of renal function. Am. J. Physiol. Renal Physiol. 310, F123-F127. doi: 10.1152/ajprenal.00394.2015
21. Gerdes, A. M., Liu, Z., and Zimmer, H. G. (1994). Changes in nuclear size of cardiac myocytes during the development and progression of hypertrophy in rats. Cardioscience 5, 203-208.
22. Girardi, A. C., Degray, B. C., Nagy, T., Biemesderfer, D., and Aronson, P. S. (2001). Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J. Biol. Chem. 276, 46671-46677. doi: 10.1074/jbc.M106897200
23. Girardi, A. C., and Di Sole, F. (2012). Deciphering the mechanisms of the Na+/H+ exchanger-3 regulation in organ dysfunction. Am. J. Physiol. Cell Physiol. 302, C1569-C1587. doi: 10.1152/ajpcell.00017.2012
24. Girardi, A. C., Fukuda, L. E., Rossoni, L. V., Malnic, G., and Reboucas, N. A. (2008). Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule. Am. J. Physiol. Renal Physiol. 294, F414-F422. doi: 10.1152/ajprenal.00174.2007
25. Gomez, N., Touihri, K., Matheeussen, V., Mendes Da Costa, A., Mahmoudabady, M., Mathieu, M., et al. (2012). Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur. J. Heart Fail. 14, 14-21. doi: 10.1093/eurjhf/hfr146
26. Gronborg, M., Kristiansen, T. Z., Stensballe, A., Andersen, J. S., Ohara, O., Mann, M., et al. (2002). A mass spectrometry-based proteomic approach for identification of serine/threonine-phosphorylated proteins by enrichment with phospho-specific antibodies: identification of a novel protein, Frigg, as a protein kinase A substrate. Mol. Cell. Proteomics 1, 517-527. doi: 10.1074/mcp.M200010-MCP200
27. Groop, P. H., Cooper, M. E., Perkovic, V., Emser, A., Woerle, H. J., and von Eynatten, M. (2013). Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 36, 3460-3468. doi: 10.2337/dc13-0323
28. Gutzwiller, J. P., Hruz, P., Huber, A. R., Hamel, C., Zehnder, C., Drewe, J., et al. (2006). Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 73, 142-150. doi: 10.1159/000094334
29. Gutzwiller, J. P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., et al. (2004). Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 89, 3055-3061. doi: 10.1210/jc.2003-031403
30. Hattori, S. (2011). Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr. J. 58, 69-73. doi: 10.1507/endocrj.K10E-382
31. Hocher, B., Sharkovska, Y., Mark, M., Klein, T., and Pfab, T. (2013). The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int. J. Cardiol. 167, 87-93. doi: 10.1016/j.ijcard.2011.12.007
32. Inoue, B. H., Arruda-Junior, D. F., Campos, L. C., Barreto, A. L., Rodrigues, M. V., Krieger, J. E., et al. (2013). Progression of microalbuminuria in SHR is associated with lower expression of critical components of the apical endocytic machinery in the renal proximal tubule. Am. J. Physiol. Renal. Physiol. 305, F216-F226. doi: 10.1152/ajprenal.00255.2012
33. Inoue, B. H., dos Santos, L., Pessoa, T. D., Antonio, E. L., Pacheco, B. P., Savignano, F. A., et al. (2012). Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302, R166-R174. doi: 10.1152/ajpregu.00127.2011
34. Jensen, E. P., Poulsen, S. S., Kissow, H., Holstein-Rathlou, N. H., Deacon, C. F., Jensen, B. L., et al. (2015). Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow. Am. J. Physiol. Renal Physiol. 308, F867-F877. doi: 10.1152/ajprenal.00527.2014
35. Kanasaki, K., Shi, S., Kanasaki, M., He, J. H., Nagai, T., Nakamura, Y., et al. (2014). Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 63, 2120-2131. doi: 10.2337/db13-1029
36. Kawasaki, I., Hiura, Y., Tamai, A., Yoshida, Y., Yakusiji, Y., Ikuno, Y., et al. (2015). Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate. J. Diabetes 7, 41-46. doi: 10.1111/1753-0407.12153
37. Kenny, A. J., Booth, A. G., George, S. G., Ingram, J., Kershaw, D., Wood, E. J., et al. (1976). Dipeptidyl peptidase IV, a kidney brush-border serine peptidase. Biochem. J. 157, 169-182. doi: 10.1042/bj1570169
38. Kestila, M., Lenkkeri, U., Mannikko, M., Lamerdin, J., McCready, P., Putaala, H., et al. (1998). Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol. Cell 1, 575-582. doi: 10.1016/S1097-2765(00)80057-X
39. Kocinsky, H. S., Girardi, A. C., Biemesderfer, D., Nguyen, T., Mentone, S., Orlowski, J., et al. (2005). Use of phospho-specific antibodies to determine the phosphorylation of endogenous Na+/H+ exchanger NHE3 at PKA consensus sites. Am. J. Physiol. Renal Physiol. 289, F249-F258. doi: 10.1152/ajprenal.00082.2004
40. Lambeir, A. M., Durinx, C., Scharpe, S., and De Meester, I. (2003). Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40, 209-294. doi: 10.1080/713609354
41. Laskar, S. R., and Dries, D. L. (2003). The prognostic significance of renal dysfunction in patients with chronic systolic heart failure. Curr. Cardiol. Rep. 5, 205-210. doi: 10.1007/s11886-003-0050-z
42. Leheste, J. R., Rolinski, B., Vorum, H., Hilpert, J., Nykjaer, A., Jacobsen, C., et al. (1999). Megalin knockout mice as an animal model of low molecular weight proteinuria. Am. J. Pathol. 155, 1361-1370. doi: 10.1016/S0002-9440(10)65238-8
43. Liu, W. J., Xie, S. H., Liu, Y. N., Kim, W., Jin, H. Y., Park, S. K., et al. (2012). Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J. Pharmacol. Exp. Ther. 340, 248-255. doi: 10.1124/jpet.111.186866
44. Luimula, P., Ahola, H., Wang, S. X., Solin, M. L., Aaltonen, P., Tikkanen, I., et al. (2000). Nephrin in experimental glomerular disease. Kidney Int. 58, 1461-1468. doi: 10.1046/j.1523-1755.2000.00308.x
45. Makino, Y., Fujita, Y., and Haneda, M. (2015). Dipeptidyl peptidase-4 inhibitors in progressive kidney disease. Curr. Opin. Nephrol. Hypertens. 24, 67-73. doi: 10.1097/MNH.0000000000000080
46. Melo, S. F., Fernandes, T., Barauna, V. G., Matos, K. C., Santos, A. A., Tucci, P. J., et al. (2014). Expression of MicroRNA-29 and collagen in cardiac muscle after swimming training in myocardial-infarcted rats. Cell. Physiol. Biochem. 33, 657-669. doi: 10.1159/000358642
47. Moreno, C., Mistry, M., and Roman, R. J. (2002). Renal effects of glucagon-like peptide in rats. Eur. J. Pharmacol. 434, 163-167. doi: 10.1016/S0014-2999(01)01542-4
48. Nakamura, T., Iwanaga, Y., Miyaji, Y., Nohara, R., Ishimura, T., and Miyazaki, S. (2016). Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up. Cardiovasc. Diabetol. 15, 54. doi: 10.1186/s12933-016-0371-z
49. New, L. A., Martin, C. E., Scott, R. P., Platt, M. J., Keyvani Chahi, A., Stringer, C. D., et al. (2016). Nephrin tyrosine phosphorylation is required to stabilize and restore podocyte foot process architecture. J. Am. Soc. Nephrol. doi: 10.1681/ASN.2015091048. [Epub ahead of print].
50. Pacheco, B. P., Crajoinas, R. O., Couto, G. K., Davel, A. P., Lessa, L. M., Rossoni, L. V., et al. (2011). Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J. Hypertens 29, 520-528. doi: 10.1097/HJH.0b013e328341939d
51. Pfaffl, M. W., Tichopad, A., Prgomet, C., and Neuvians, T. P. (2004). Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: bestKeeper-Excel-based tool using pair-wise correlations. Biotechnol. Lett. 26, 509-515. doi: 10.1023/B:BILE.0000019559.84305.47
52. Pontes, R. B., Crajoinas, R. O., Nishi, E. E., Oliveira-Sales, E. B., Girardi, A. C., Campos, R. R., et al. (2015). Renal nerve stimulation leads to the activation of the Na+/H+ exchanger isoform 3 via angiotensin II type I receptor. Am. J. Physiol. Renal Physiol. 308, F848-F856. doi: 10.1152/ajprenal.00515.2014
53. Ravassa, S., Zudaire, A., Carr, R. D., and Diez, J. (2011). Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 300, H1361-H1372. doi: 10.1152/ajpheart.00885.2010
54. Rieg, T., Gerasimova, M., Murray, F., Masuda, T., Tang, T., Rose, M., et al. (2012). Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am. J. Physiol. Renal Physiol. 303, F963-F971. doi: 10.1152/ajprenal.00259.2012
55. Sauvé, M., Ban, K., Momen, M. A., Zhou, Y. Q., Henkelman, R. M., Husain, M., et al. (2010). Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 59, 1063-1073. doi: 10.4103/0019-5049.163003
56. Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., et al. (2014). Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130, 1579-1588. doi: 10.1161/CIRCULATIONAHA.114.010389
57. Sharkovska, Y., Reichetzeder, C., Alter, M., Tsuprykov, O., Bachmann, S., Secher, T., et al. (2014). Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. J. Hypertens 32, 2211-2223. discussion: 2223. doi: 10.1097/HJH.0000000000000328
58. Shigeta, T., Aoyama, M., Bando, Y. K., Monji, A., Mitsui, T., Takatsu, M., et al. (2012). Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation 126, 1838-1851. doi: 10.1161/CIRCULATIONAHA.112.096479
59. Skov, J., Dejgaard, A., Frokiaer, J., Holst, J. J., Jonassen, T., Rittig, S., et al. (2013). Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J. Clin. Endocrinol. Metab. 98, E664-E671. doi: 10.1210/jc.2012-3855
60. Thomson, S. C., Kashkouli, A., and Singh, P. (2013). Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. Am. J. Physiol. Renal Physiol. 304, F137-F144. doi: 10.1152/ajprenal.00064.2012
61. Timmers, L., Henriques, J. P., de Kleijn, D. P., Devries, J. H., Kemperman, H., Steendijk, P., et al. (2009). Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol. 53, 501-510. doi: 10.1016/j.jacc.2008.10.033
62. Tryggvason, K. (1999). Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J. Am. Soc. Nephrol. 10, 2440-2445.
63. Tsuprykov, O., Ando, R., Reichetzeder, C., von Websky, K., Antonenko, V., Sharkovska, Y., et al. (2016). The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney Int. 89, 1049-1061. doi: 10.1016/j.kint.2016.01.016
64. Udani, S. M., and Koyner, J. L. (2010). The effects of heart failure on renal function. Cardiol. Clin. 28, 453-465. doi: 10.1016/j.ccl.2010.04.004
65. Ussher, J. R., and Drucker, D. J. (2012). Cardiovascular biology of the incretin system. Endocr. Rev. 33, 187-215. doi: 10.1210/er.2011-1052
66. van Rooij, E., Sutherland, L. B., Thatcher, J. E., DiMaio, J. M., Naseem, R. H., Marshall, W. S., et al. (2008). Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. U.S.A. 105, 13027-13032. doi: 10.1073/pnas.0805038105
67. Willnow, T. E., Hilpert, J., Armstrong, S. A., Rohlmann, A., Hammer, R. E., Burns, D. K., et al. (1996). Defective forebrain development in mice lacking gp330/megalin. Proc. Natl. Acad. Sci. U.S.A. 93, 8460-8464. doi: 10.1073/pnas.93.16.8460
68. Yin, M., Sillje, H. H., Meissner, M., van Gilst, W. H., and de Boer, R. A. (2011). Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc. Diabetol. 10:85. doi: 10.1186/1475-2840-10-85
69. Zaruba, M. M., Theiss, H. D., Vallaster, M., Mehl, U., Brunner, S., David, R., et al. (2009). Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 4, 313-323. doi: 10.1016/j.stem.2009.02.013